The Sunburn in Your Medicine Cabinet: How Photosensitizing Medications Amplify Ordinary Sunlight

Key Takeaways:

• Photosensitizing drugs absorb ultraviolet radiation — mostly in the UVA band, 320 to 400 nanometers — and convert that energy into free radicals and reactive oxygen species inside the skin, producing an exaggerated sunburn at UV doses that would not otherwise redden that person.
• The drugs most frequently reported to cause phototoxicity are vemurafenib, voriconazole, doxycycline, hydrochlorothiazide, amiodarone, and chlorpromazine.
• In a Danish nationwide case-control study, high cumulative hydrochlorothiazide use (50,000 mg or more) was associated with a roughly four-fold increase in squamous cell carcinoma, rising to about seven-fold at cumulative doses of 200,000 mg or more.

July is UV Safety Month, and a meaningful share of the burn risk is sitting in the medicine cabinet rather than in the sky. Photosensitizing medications are drugs whose molecules behave as chromophores: small, planar, often polycyclic structures that absorb ultraviolet or visible radiation, most of the clinically relevant absorption falling in the UVA band between 320 and 400 nanometers. Absorption itself is not the injury. The captured photon lifts the drug into an excited state, and that excited molecule discharges its energy into neighboring oxygen and biomolecules, generating free radicals and reactive oxygen species — singlet oxygen, superoxide — directly inside keratinocytes. What follows is lipid peroxidation of cell membranes, oxidative DNA damage, and keratinocyte death, which the patient experiences as an exaggerated, sharply demarcated sunburn confined to sun-exposed skin. Because UVA penetrates deeply and passes straight through window glass, a phototoxic burn can appear at sun doses that would never redden that person otherwise. The molecules reported most often are vemurafenib, voriconazole, doxycycline, hydrochlorothiazide, amiodarone, and chlorpromazine.

Hydrochlorothiazide deserves separate attention, because its risk does not end when the burn fades. A nationwide Danish case-control study drew nonmelanoma skin cancer cases from the Danish Cancer Registry, matched them 1:20 to controls by age and sex, and reconstructed cumulative thiazide exposure from the national prescription registry. High use — 50,000 mg or more cumulatively, on the order of five to eleven years of standard 12.5 to 25 mg daily dosing — carried an odds ratio of 3.98 for squamous cell carcinoma and 1.29 for basal cell carcinoma. The dose-response curve was clean rather than suggestive: at cumulative exposures of 200,000 mg or more, the odds ratio for squamous cell carcinoma reached 7.38. Other diuretics and other antihypertensives showed no such association, which points the finger at the molecule rather than at blood pressure or at the sort of person who ends up on a diuretic. The chlorine substituent on the thiazide ring is the structural culprit; photodegradation of chlorinated drugs yields reactive intermediates that attack DNA. Intellectual honesty requires one caveat: a systematic review of 240 studies covering 129 implicated drugs found that most drug-phototoxicity associations rest on low-quality evidence, with the strongest support behind vemurafenib, NSAIDs, fluoroquinolones, and tetracyclines.

How do you manage photosensitizing medications without stopping the drug?

Most of the work is prevention, and most of it is unglamorous. A phototoxic reaction is dose-dependent in both directions — it scales with drug concentration in the skin and with UV dose — so lowering either limb blunts it, and the reaction reverses on withdrawal or substitution of the offending agent. Because UVA is the operative waveband, a high-SPF sunscreen chosen for UVB coverage alone is close to useless here; the requirement is genuine broad-spectrum protection, plus the recognition that UVA is undiminished by clouds and by window glass. For a patient on long-term hydrochlorothiazide with fair skin, a history of sun damage, or an existing keratinocyte carcinoma, the finding that no other antihypertensive class carries the same signal makes substitution a rational conversation rather than an alarmist one, and sustained high cumulative exposure argues for periodic skin surveillance. For doxycycline, amiodarone, and voriconazole, the same logic applies with different arithmetic. None of this means the drug is wrong; it means the prescription and the sun exposure have to be read together, which is exactly what a periodic medication review is for.

References:

1. Moore, D. E. (2002). Drug-induced cutaneous photosensitivity: Incidence, mechanism, prevention and management. Drug Safety, 25(5), 345-372.
2. Kim, W. B., Shelley, A. J., Novice, K., Joo, J., Lim, H. W., & Glassman, S. J. (2018). Drug-induced phototoxicity: A systematic review. Journal of the American Academy of Dermatology, 79(6), 1069-1075.
3. Pedersen, S. A., Gaist, D., Schmidt, S. A. J., Hölmich, L. R., Friis, S., & Pottegård, A. (2018). Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. Journal of the American Academy of Dermatology, 78(4), 673-681.e9.